1. Home
  2. CION vs BCYC Comparison

CION vs BCYC Comparison

Compare CION & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CION
  • BCYC
  • Stock Information
  • Founded
  • CION 2011
  • BCYC 2009
  • Country
  • CION United States
  • BCYC United Kingdom
  • Employees
  • CION N/A
  • BCYC N/A
  • Industry
  • CION Finance/Investors Services
  • BCYC Biotechnology: Pharmaceutical Preparations
  • Sector
  • CION Finance
  • BCYC Health Care
  • Exchange
  • CION Nasdaq
  • BCYC Nasdaq
  • Market Cap
  • CION 491.6M
  • BCYC 511.4M
  • IPO Year
  • CION N/A
  • BCYC 2019
  • Fundamental
  • Price
  • CION $9.45
  • BCYC $7.39
  • Analyst Decision
  • CION Sell
  • BCYC Buy
  • Analyst Count
  • CION 2
  • BCYC 8
  • Target Price
  • CION $11.50
  • BCYC $29.14
  • AVG Volume (30 Days)
  • CION 525.6K
  • BCYC 438.9K
  • Earning Date
  • CION 05-08-2025
  • BCYC 05-01-2025
  • Dividend Yield
  • CION 16.35%
  • BCYC N/A
  • EPS Growth
  • CION N/A
  • BCYC N/A
  • EPS
  • CION 0.63
  • BCYC N/A
  • Revenue
  • CION $252,432,000.00
  • BCYC $35,275,000.00
  • Revenue This Year
  • CION N/A
  • BCYC N/A
  • Revenue Next Year
  • CION N/A
  • BCYC $0.27
  • P/E Ratio
  • CION $14.93
  • BCYC N/A
  • Revenue Growth
  • CION 0.57
  • BCYC 30.76
  • 52 Week Low
  • CION $8.51
  • BCYC $6.10
  • 52 Week High
  • CION $12.71
  • BCYC $28.67
  • Technical
  • Relative Strength Index (RSI)
  • CION 40.16
  • BCYC 40.27
  • Support Level
  • CION $8.54
  • BCYC $6.10
  • Resistance Level
  • CION $9.39
  • BCYC $8.00
  • Average True Range (ATR)
  • CION 0.42
  • BCYC 0.61
  • MACD
  • CION 0.02
  • BCYC 0.14
  • Stochastic Oscillator
  • CION 45.85
  • BCYC 46.07

About CION CION Investment Corporation

CION Invt Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The Company's portfolio is comprised of investments in senior secured debt, including first lien loans, second lien loans, and unitranche loans, and, to a lesser extent, collateralized securities, structured products and other similar securities, unsecured debt, and equity, of private and thinly-traded U.S. middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation for investors.

About BCYC Bicycle Therapeutics plc

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.

Share on Social Networks: